Logo Neurocrine Biosciences

Neurocrine Biosciences (NBIX) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Neurocrine Biosciences · Health Care · ref. ETF XLV · 136 calls · price $135.13
🏆JPI 2026 portfoliosSee tracking →
What the company does: Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

📈 Neurocrine Biosciences (NBIX) stock price

$135.13-1.5% over range
Oct 14, 25low $123.1 · high $185.5Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
89% recommend buying · 18 analysts
📊 JPI status : Neurocrine Biosciences is no longer in our current JPI rankings, but appeared in the past (2022) — its upside may be behind it. See the stocks picked in 2022 →

🎯 NBIX price target & analyst consensus — price $135

The price target · all analysts combined (18 targets)
Highest target · 1 firm of 18$253+87.2%
Median target · of 18 targets$210+55.4%
Lowest target · 1 firm of 18$150+11.0%
Current price$135.13
Where these 18 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 18100% $150 ↔ $253
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (53 calls tested). It aims for $222 (+64 %), call made on August 1, 2026, maturing on August 1, 2027 (74 d ago).

The 11 reliable analysts $214+58 %
The 7 other firms $185+37 %
How to read it: the 11 reliable firms are not filtered by optimism — 11 aim above the price, 0 below, hence their $214 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 18 ratings (last 6 months)
Strong Buy00%
Buy1689%
Hold211%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Neurocrine Biosciences? The JPI assistant answers using our backtest data.

📈 Neurocrine Biosciences fundamentals: valuation, margins & growth › open the full page

P/E 19.8Net margin 20.9 %Revenue growth +39.5 %Cheap for the growth

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 10 %
2023
Rev +27%Profit +62%
2024
Rev +25%Profit +37%
2025
Rev +21%Profit +40%

🔎 Detailed analyses

✅ Historical analyst reliability on NBIX

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Credit Suisse 100% +42.2% 2
Piper Sandler ↗ 100% +33.6% 7
Goldman Sachs ↗ 100% +25.8% 4
RBC Capital ↗ 100% +25.6% 7
Jefferies ↗ 86% +84.6% 7
Deutsche Bank ↗ 75% +28.3% 8
Needham ↗ 75% +22.6% 4
Evercore ISI Group ↗ 75% +12.3% 4
UBS ↗ 70% +17.2% 10
Wedbush ↗ 70% +8.2% 10
See the other 14 firms
BMO Capital ↗ 33% +4.0% 3
JP Morgan ↗ 40% +0.5% 15
Baird ↗ 40% +7.6% 5
Morgan Stanley ↗ 48% +4.1% 21
Raymond James ↗ 50% -1.1% 4
Cantor Fitzgerald ↗ 50% +1.9% 10
Barclays ↗ 57% +9.2% 14
Oppenheimer ↗ 57% +20.1% 14
Stifel ↗ 60% +9.0% 5
Canaccord Genuity ↗ 60% +10.7% 15
Guggenheim ↗ 67% +13.4% 6
B of A Securities ↗ 67% +21.9% 3
Citigroup ↗ 67% +23.8% 6
HC Wainwright & Co. ↗ 70% +7.5% 20

📊 What $1,000 invested in Neurocrine Biosciences would be worth › open the full page

In short — $1,000 invested in Neurocrine Biosciences 10 years ago would be worth $2,979 today, i.e. +12%/yr on average. Best year: 2017 (+100%), worst: 2016 (-32%). Price performance, excluding dividends.

If I'd invested $1,000 in Neurocrine Biosciences

InvestmentWorth todayGain
1 years ago$1,235+23%
3 years ago$1,411+41%
5 years ago$1,758+76%
→ See Neurocrine Biosciences's full return history + gain calculator

Return by year (Neurocrine Biosciences)

YearReturn$1,000 invested at year start
2026 (YTD)+19%$1,188 (+19%)
2025+4%$1,235 (+23%)
2024+4%$1,279 (+28%)
→ See Neurocrine Biosciences's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Neurocrine Biosciences

Loading news…

📋 All analyst calls on NBIX

BMO Capital ↗
Oct 12, 26
■ Market Perform neutral · not a buy · 🎯$150
Price at call : $135.13 — gap to target +11%
Today : $135.13 — gap to target +11%
🎯 on NBIX : no call matured yet · 📊 on Health : 45.7% · +6.4% (35 calls)
in progress (365j)
matures : Oct 12, 27
UBS ↗
Sep 29, 26
▲ Buy · 🎯$214
Price at call : $141.84 — upside +51%
Today : $135.13 — upside +58%
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Sep 29, 27
Morgan Stanley ↗
Sep 11, 26
■ Equal-Weight neutral · not a buy · 🎯$183
Price at call : $157.22 — gap to target +16%
Today : $135.13 — gap to target +35%
🎯 on NBIX : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Sep 11, 27
RBC Capital ↗
Sep 8, 26
▲ Outperform · 🎯$198
Price at call : $155.14 — upside +28%
Today : $135.13 — upside +47%
🎯 on NBIX : no call matured yet · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Sep 8, 27
Citigroup ↗
Sep 3, 26
▲ Buy · 🎯$253
Price at call : $155.64 — upside +63%
Today : $135.13 — upside +87%
🎯 on NBIX : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Sep 3, 27
Morgan Stanley ↗
Aug 13, 26
■ Equal-Weight neutral · not a buy · 🎯$182
Price at call : $152.72 — gap to target +19%
Today : $135.13 — gap to target +35%
🎯 on NBIX : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Aug 13, 27
▲ Buy · 🎯$210
Price at call : $166.06 — upside +26%
Today : $135.13 — upside +55%
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Aug 3, 27
▲ Buy · 🎯$213
Price at call : $166.06 — upside +28%
Today : $135.13 — upside +58%
🎯 on NBIX : no call matured yet · 📊 on Health : 59.1% · +6.4% (110 calls)
in progress (365j)
matures : Aug 3, 27
See the other 128 calls, newest to oldest
Wedbush ↗
Aug 3, 26
▲ Outperform · 🎯$194
Price at call : $166.23 — upside +17%
Today : $135.13 — upside +44%
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
in progress (365j)
matures : Aug 3, 27
Citigroup ↗
Jul 31, 26
▲ Buy · 🎯$249
Price at call : $166.23 — upside +50%
Today : $135.13 — upside +84%
🎯 on NBIX : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Jul 31, 27
RBC Capital ↗
Jul 31, 26
▲ Outperform · 🎯$198
Price at call : $166.23 — upside +19%
Today : $135.13 — upside +47%
🎯 on NBIX : no call matured yet · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Jul 31, 27
Morgan Stanley ↗
Jul 31, 26
■ Equal-Weight neutral · not a buy · 🎯$196
Price at call : $166.23 — gap to target +18%
Today : $135.13 — gap to target +45%
🎯 on NBIX : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Jul 31, 27
TD Cowen ↗
Jul 31, 26
▲ Buy · 🎯$220
Price at call : $166.23 — upside +32%
Today : $135.13 — upside +63%
🎯 on NBIX : no call matured yet · 📊 on Health : 55.6% · +19.8% (27 calls)
in progress (365j)
matures : Jul 31, 27
Piper Sandler ↗
Jul 31, 26
▲ Overweight · 🎯$210
Price at call : $166.23 — upside +26%
Today : $135.13 — upside +55%
🎯 on NBIX : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : Jul 31, 27
▲ Overweight · 🎯$215
Price at call : $166.23 — upside +29%
Today : $135.13 — upside +59%
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
in progress (365j)
matures : Jul 31, 27
Guggenheim ↗
Jul 31, 26
▲ Buy · 🎯$222
Price at call : $166.23 — upside +34%
Today : $135.13 — upside +64%
🎯 on NBIX : 67% (6 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jul 31, 27
Stifel ↗
Jul 31, 26
▲ Buy · 🎯$215
Price at call : $166.23 — upside +29%
Today : $135.13 — upside +59%
🎯 on NBIX : no call matured yet · 📊 on Health : 48% · +12.3% (100 calls)
in progress (365j)
matures : Jul 31, 27
Needham ↗
Jul 31, 26
▲ Buy · 🎯$204
Price at call : $166.8 — upside +22%
Today : $135.13 — upside +51%
🎯 on NBIX : no call matured yet · 📊 on Health : 47.2% · +2.5% (142 calls)
in progress (365j)
matures : Jul 31, 27
Guggenheim ↗
Jul 21, 26
▲ Buy · 🎯$200
Price at call : $172.69 — upside +16%
Today : $135.13 — upside +48%
🎯 on NBIX : 67% (6 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : Jul 21, 27
Wells Fargo ↗
Jul 17, 26
▲ Overweight · 🎯$200
Price at call : $173 — upside +16%
Today : $135.13 — upside +48%
🎯 on NBIX : no call matured yet · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Jul 17, 27
▲ Buy · 🎯$200
Price at call : $172.04 — upside +16%
Today : $135.13 — upside +48%
🎯 on NBIX : no call matured yet · 📊 on Health : 59.1% · +6.4% (110 calls)
in progress (365j)
matures : Jul 13, 27
BMO Capital ↗
Jul 13, 26
■ Market Perform neutral · not a buy · 🎯$170
Price at call : $174.1 — gap to target -2%
Today : $135.13 — gap to target +26%
🎯 on NBIX : no call matured yet · 📊 on Health : 45.7% · +6.4% (35 calls)
in progress (365j)
matures : Jul 13, 27
RBC Capital ↗
Jul 7, 26
▲ Outperform · 🎯$195
Price at call : $178.24 — upside +9%
Today : $135.13 — upside +44%
🎯 on NBIX : no call matured yet · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Jul 7, 27
UBS ↗
Jun 30, 26
▲ Buy · 🎯$208
Price at call : $167.77 — upside +24%
Today : $135.13 — upside +54%
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
in progress (365j)
matures : Jun 30, 27
RBC Capital ↗
May 29, 26
▲ Outperform · 🎯$183
Price at call : $161 — upside +14%
Today : $135.13 — upside +35%
🎯 on NBIX : no call matured yet · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : May 29, 27
Bernstein ↗
May 22, 26
▲ Outperform · 🎯$221
Price at call : $155.73 — upside +42%
Today : $135.13 — upside +64%
🎯 on NBIX : no call matured yet · 📊 on Health : 42.9% · -5.6% (7 calls)
in progress (365j)
matures : May 22, 27
JP Morgan ↗
May 8, 26
▲ Overweight · 🎯$185
Price at call : $150.59 — upside +23%
Today : $135.13 — upside +37%
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : May 8, 27
▲ Buy · 🎯$155
Price at call : $152.25 — upside +2%
Today : $135.13 — upside +15%
🎯 on NBIX : no call matured yet · 📊 on Health : 59.1% · +6.4% (110 calls)
in progress (365j)
matures : May 7, 27
Citigroup ↗
May 6, 26
▲ Buy · 🎯$246
Price at call : $149.59 — upside +64%
Today : $135.13 — upside +82%
🎯 on NBIX : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : May 6, 27
■ Equal-Weight neutral · not a buy · 🎯$191
Price at call : $149.59 — gap to target +28%
Today : $135.13 — gap to target +41%
🎯 on NBIX : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : May 6, 27
RBC Capital ↗
May 6, 26
▲ Outperform · 🎯$180
Price at call : $149.59 — upside +20%
Today : $135.13 — upside +33%
🎯 on NBIX : no call matured yet · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : May 6, 27
Piper Sandler ↗
May 6, 26
▲ Overweight · 🎯$207
Price at call : $149.59 — upside +38%
Today : $135.13 — upside +53%
🎯 on NBIX : no call matured yet · 📊 on Health : 42.5% · +4.1% (120 calls)
in progress (365j)
matures : May 6, 27
Guggenheim ↗
May 6, 26
▲ Buy · 🎯$175
Price at call : $149.59 — upside +17%
Today : $135.13 — upside +30%
🎯 on NBIX : 67% (6 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
in progress (365j)
matures : May 6, 27
Wedbush ↗
May 6, 26
▲ Outperform · 🎯$176
Price at call : $147.02 — upside +20%
Today : $135.13 — upside +30%
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
in progress (365j)
matures : May 6, 27
▲ Outperform · 🎯$170
Price at call : $130.19 — upside +31%
Today : $135.13 — upside +26%
🎯 on NBIX : no call matured yet · 📊 on Health : 58.3% · +20.9% (12 calls)
in progress (365j)
matures : Apr 22, 27
Morgan Stanley ↗
Apr 10, 26
■ Equal-Weight neutral · not a buy · 🎯$185
Price at call : $126.32 — gap to target +46%
Today : $135.13 — gap to target +37%
🎯 on NBIX : no call matured yet · 📊 on Health : 42% · -0.8% (200 calls)
in progress (365j)
matures : Apr 10, 27
Citigroup ↗
Apr 7, 26
▲ Buy · 🎯$242
Price at call : $133.15 — upside +82%
Today : $135.13 — upside +79%
🎯 on NBIX : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Apr 7, 27
▲ Buy · 🎯$200
Price at call : $133.15 — upside +50%
Today : $135.13 — upside +48%
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
in progress (365j)
matures : Apr 7, 27
Wedbush ↗
Apr 7, 26
▲ Outperform · 🎯$166
Price at call : $130.9 — upside +27%
Today : $135.13 — upside +23%
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
in progress (365j)
matures : Apr 7, 27
▲ Buy · 🎯$215
Price at call : $130.9 — upside +64%
Today : $135.13 — upside +59%
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Apr 7, 27
Needham ↗
Apr 6, 26
▲ Buy · 🎯$185
Price at call : $130.9 — upside +41%
Today : $135.13 — upside +37%
🎯 on NBIX : no call matured yet · 📊 on Health : 47.2% · +2.5% (142 calls)
in progress (365j)
matures : Apr 6, 27
JP Morgan ↗
Mar 12, 26
▲ Overweight · 🎯$177
Price at call : $129.78 — upside +36%
Today : $135.13 — upside +31%
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Mar 12, 27
Wolfe Research ↗
Feb 24, 26
▲ Outperform · 🎯$160
Price at call : $130.96 — upside +22%
Today : $135.13 — upside +18%
🎯 on NBIX : no call matured yet · 📊 on Health : 46.2% · +2.9% (13 calls)
in progress (365j)
matures : Feb 24, 27
JP Morgan ↗
Feb 17, 26
▲ Overweight · 🎯$176
Price at call : $128.38 — upside +37%
Today : $135.13 — upside +30%
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
in progress (365j)
matures : Feb 17, 27
▲ Buy · 🎯$140
Price at call : $128.38 — upside +9%
Today : $135.13 — upside +4%
🎯 on NBIX : no call matured yet · 📊 on Health : 59.1% · +6.4% (110 calls)
in progress (365j)
matures : Feb 17, 27
Wells Fargo ↗
Feb 13, 26
▲ Overweight · 🎯$175
Price at call : $127.76 — upside +37%
Today : $135.13 — upside +30%
🎯 on NBIX : no call matured yet · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Feb 13, 27
Citigroup ↗
Feb 12, 26
▲ Buy · 🎯$204
Price at call : $124.12 — upside +64%
Today : $135.13 — upside +51%
🎯 on NBIX : no call matured yet · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Feb 12, 27
RBC Capital ↗
Feb 12, 26
▲ Outperform · 🎯$177
Price at call : $124.12 — upside +43%
Today : $135.13 — upside +31%
🎯 on NBIX : no call matured yet · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Feb 12, 27
BMO Capital ↗
Feb 12, 26
■ Market Perform neutral · not a buy · 🎯$140
Price at call : $124.12 — gap to target +13%
Today : $135.13 — gap to target +4%
🎯 on NBIX : no call matured yet · 📊 on Health : 45.7% · +6.4% (35 calls)
in progress (365j)
matures : Feb 12, 27
Wedbush ↗
Feb 12, 26
▲ Outperform · 🎯$151
Price at call : $124.12 — upside +22%
Today : $135.13 — upside +12%
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
in progress (365j)
matures : Feb 12, 27
▲ Buy · 🎯$192
Price at call : $123.1 — upside +56%
Today : $135.13 — upside +42%
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Feb 12, 27
▲ Buy · 🎯$198
Price at call : $141.7 — upside +40%
Today : $135.13 — upside +47%
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
in progress (365j)
matures : Dec 17, 26
UBS ↗
Oct 9, 25
▲ Buy · 🎯$195
Price at call : $136.63 — upside +43%
Today : $135.13 — upside +44%
Expected +43% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
+3.5%
stock +3% · XLV +21%
matured Oct 9, 26
JP Morgan ↗
Aug 6, 25
▲ Overweight · 🎯$171
Price at call : $125.6 — upside +36%
Today : $135.13 — upside +27%
Expected +36% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
+30.1%
stock +30% · XLV +28%
matured Aug 6, 26
Guggenheim ↗
Aug 1, 25
▲ Buy · 🎯$175
Price at call : $128.04 — upside +37%
Today : $135.13 — upside +30%
Expected +37% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (6 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
+29.8%
stock +30% · XLV +22%
matured Aug 1, 26
Wedbush ↗
Jul 31, 25
▲ Outperform · 🎯$141
Price at call : $128.23 — upside +10%
Today : $135.13 — upside +4%
Expected +10% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
+30.1%
stock +30% · XLV +25%
matured Jul 31, 26
UBS ↗
Jul 9, 25
▲ Buy · 🎯$174
Price at call : $134.92 — upside +29%
Today : $135.13 — upside +29%
Expected +29% · Actual +31% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
+31.3%
stock +31% · XLV +18%
matured Jul 9, 26
Guggenheim ↗
May 6, 25
▲ Buy · 🎯$165
Price at call : $121.61 — upside +36%
Today : $135.13 — upside +22%
Expected +36% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (6 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
+23.0%
stock +23% · XLV +7%
matured May 6, 26
UBS ↗
May 6, 25
▲ Buy · 🎯$152
Price at call : $121.61 — upside +25%
Today : $135.13 — upside +12%
Expected +25% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
+23.0%
stock +23% · XLV +7%
matured May 6, 26
▲ Buy · 🎯$160
Price at call : $118.92 — upside +35%
Today : $135.13 — upside +18%
Expected +35% · Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+23.6%
stock +24% · XLV +8%
matured May 6, 26
▲ Buy · 🎯$158
Price at call : $106.46 — upside +48%
Today : $135.13 — upside +17%
Expected +48% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+20.3%
stock +20% · XLV +4%
matured Apr 28, 26
▲ Buy · 🎯$168
Price at call : $101.74 — upside +65%
Today : $135.13 — upside +24%
Expected +65% · Actual +29% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+28.9%
stock +29% · XLV +8%
matured Apr 22, 26
UBS ↗
Apr 4, 25
▲ Buy · 🎯$137
Price at call : $93.25 — upside +47%
Today : $135.13 — upside +1%
Expected +47% · Actual +42% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
+42.1%
stock +42% · XLV +9%
matured Apr 4, 26
▲ Buy · 🎯$185
Price at call : $119.11 — upside +55%
Today : $135.13 — upside +37%
Expected +55% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+10.0%
stock +10% · XLV +7%
matured Feb 24, 26
▲ Buy · 🎯$185
Price at call : $120.69 — upside +53%
Today : $135.13 — upside +37%
Expected +53% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+6.4%
stock +6% · XLV +8%
matured Feb 21, 26
Guggenheim ↗
Feb 10, 25
▲ Buy · 🎯$163
Price at call : $118.81 — upside +37%
Today : $135.13 — upside +21%
Expected +37% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (6 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
+15.9%
stock +16% · XLV +6%
matured Feb 10, 26
▲ Buy · 🎯$185
Price at call : $118.81 — upside +56%
Today : $135.13 — upside +37%
Expected +56% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+15.9%
stock +16% · XLV +6%
matured Feb 10, 26
Wedbush ↗
Feb 7, 25
▲ Outperform · 🎯$147
Price at call : $118.81 — upside +24%
Today : $135.13 — upside +9%
Expected +24% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
+17.5%
stock +17% · XLV +7%
matured Feb 7, 26
▲ Buy · 🎯$163
Price at call : $118.81 — upside +37%
Today : $135.13 — upside +21%
Expected +37% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+17.5%
stock +17% · XLV +7%
matured Feb 7, 26
▲ Buy · 🎯$185
Price at call : $122.62 — upside +51%
Today : $135.13 — upside +37%
Expected +51% · Actual +14% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+13.8%
stock +14% · XLV +7%
matured Feb 7, 26
UBS ↗
Jan 31, 25
▲ Buy · 🎯$176
Price at call : $151.82 — upside +16%
Today : $135.13 — upside +30%
Expected +16% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
-9.3%
stock -9% · XLV +6%
matured Jan 31, 26
UBS ↗
Jan 8, 25
▲ Buy · 🎯$162
Price at call : $140.9 — upside +15%
Today : $135.13 — upside +20%
Expected +15% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
-3.6%
stock -4% · XLV +13%
matured Jan 8, 26
Wedbush ↗
Dec 16, 24
▲ Outperform · 🎯$148
Price at call : $133.05 — upside +11%
Today : $135.13 — upside +10%
Expected +11% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
+11.8%
stock +12% · XLV +11%
matured Dec 16, 25
▲ Buy · 🎯$190
Price at call : $133.05 — upside +43%
Today : $135.13 — upside +41%
Expected +43% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+11.8%
stock +12% · XLV +11%
matured Dec 16, 25
▲ Buy · 🎯$190
Price at call : $122.21 — upside +55%
Today : $135.13 — upside +41%
Expected +55% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+16.2%
stock +16% · XLV -2%
matured Nov 1, 25
▲ Overweight · 🎯$155
Price at call : $122.31 — upside +27%
Today : $135.13 — upside +15%
Expected +27% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+16.7%
stock +17% · XLV -12%
matured Sep 16, 25
▲ Overweight · 🎯$155
Price at call : $127.06 — upside +22%
Today : $135.13 — upside +15%
Expected +22% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+11.7%
stock +12% · XLV -12%
matured Aug 29, 25
▲ Buy · 🎯$190
Price at call : $128.43 — upside +48%
Today : $135.13 — upside +41%
Expected +48% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
+8.7%
stock +9% · XLV -12%
matured Aug 29, 25
JP Morgan ↗
Aug 7, 24
▲ Overweight · 🎯$181
Price at call : $146.73 — upside +23%
Today : $135.13 — upside +34%
Expected +23% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-14.8%
stock -15% · XLV -13%
matured Aug 7, 25
▲ Buy · 🎯$190
Price at call : $145.63 — upside +30%
Today : $135.13 — upside +41%
Expected +30% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
-11.8%
stock -12% · XLV -12%
matured Aug 5, 25
Guggenheim ↗
Aug 2, 24
▲ Buy · 🎯$180
Price at call : $147.7 — upside +22%
Today : $135.13 — upside +33%
Expected +22% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (6 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
-13.3%
stock -13% · XLV -9%
matured Aug 2, 25
Oppenheimer ↗
Aug 2, 24
▲ Outperform · 🎯$219
Price at call : $147.7 — upside +48%
Today : $135.13 — upside +62%
Expected +48% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
-13.3%
stock -13% · XLV -9%
matured Aug 2, 25
▲ Overweight · 🎯$155
Price at call : $146.8 — upside +6%
Today : $135.13 — upside +15%
Expected +6% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
-8.9%
stock -9% · XLV -10%
matured Jul 25, 25
JP Morgan ↗
Jul 10, 24
▲ Overweight · 🎯$173
Price at call : $146.5 — upside +18%
Today : $135.13 — upside +28%
Expected +18% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-8.9%
stock -9% · XLV -8%
matured Jul 10, 25
Wedbush ↗
May 29, 24
▲ Outperform · 🎯$152
Price at call : $134.62 — upside +13%
Today : $135.13 — upside +12%
Expected +13% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
-8.1%
stock -8% · XLV -7%
matured May 29, 25
UBS ↗
May 28, 24
▲ Buy · 🎯$193
Price at call : $140.48 — upside +37%
Today : $135.13 — upside +43%
Expected +37% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
-12.4%
stock -12% · XLV -8%
matured May 28, 25
▲ Buy · 🎯$164
Price at call : $140.71 — upside +17%
Today : $135.13 — upside +21%
Expected +17% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-22.0%
stock -22% · XLV -2%
matured May 2, 25
Guggenheim ↗
May 2, 24
▲ Buy · 🎯$170
Price at call : $140.71 — upside +21%
Today : $135.13 — upside +26%
Expected +21% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (6 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
-22.0%
stock -22% · XLV -2%
matured May 2, 25
Oppenheimer ↗
May 2, 24
▲ Outperform · 🎯$216
Price at call : $139.83 — upside +54%
Today : $135.13 — upside +60%
Expected +54% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
-21.6%
stock -22% · XLV -1%
matured May 2, 25
▲ Buy · 🎯$160
Price at call : $139.83 — upside +14%
Today : $135.13 — upside +18%
Expected +14% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
-21.6%
stock -22% · XLV -1%
matured May 2, 25
Oppenheimer ↗
Apr 24, 24
▲ Outperform · 🎯$200
Price at call : $138.97 — upside +44%
Today : $135.13 — upside +48%
Expected +44% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
-23.9%
stock -24% · XLV -2%
matured Apr 24, 25
▲ Buy · 🎯$150
Price at call : $138.97 — upside +8%
Today : $135.13 — upside +11%
Expected +8% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
-23.9%
stock -24% · XLV -2%
matured Apr 24, 25
Wedbush ↗
Apr 17, 24
▲ Outperform · 🎯$147
Price at call : $132.54 — upside +11%
Today : $135.13 — upside +9%
Expected +11% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
-24.0%
stock -24% · XLV -4%
matured Apr 17, 25
▲ Overweight · 🎯$155
Price at call : $135.93 — upside +14%
Today : $135.13 — upside +15%
Expected +14% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
-33.1%
stock -33% · XLV -3%
matured Apr 10, 25
JP Morgan ↗
Mar 20, 24
▲ Overweight · 🎯$158
Price at call : $140.65 — upside +12%
Today : $135.13 — upside +17%
Expected +12% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-21.7%
stock -22% · XLV +1%
matured Mar 20, 25
Oppenheimer ↗
Mar 13, 24
▲ Outperform · 🎯$200
Price at call : $141.8 — upside +41%
Today : $135.13 — upside +48%
Expected +41% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
-23.1%
stock -23% · XLV -2%
matured Mar 13, 25
JP Morgan ↗
Feb 23, 24
▲ Overweight · 🎯$148
Price at call : $135.58 — upside +9%
Today : $135.13 — upside +10%
Expected +9% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-12.2%
stock -12% · XLV +0%
matured Feb 22, 25
▲ Buy · 🎯$150
Price at call : $117.28 — upside +28%
Today : $135.13 — upside +11%
Expected +28% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+10.1%
stock +10% · XLV +10%
matured Dec 6, 24
Oppenheimer ↗
Oct 6, 23
▲ Outperform · 🎯$165
Price at call : $113.93 — upside +45%
Today : $135.13 — upside +22%
Expected +45% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
-1.6%
stock -2% · XLV +16%
matured Oct 5, 24
▲ Buy · 🎯$150
Price at call : $113.93 — upside +32%
Today : $135.13 — upside +11%
Expected +32% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 69% · +25.4% (248 calls)
-1.6%
stock -2% · XLV +16%
matured Oct 5, 24
▲ Buy · 🎯$144
Price at call : $113.78 — upside +27%
Today : $135.13 — upside +7%
Expected +27% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+7.4%
stock +7% · XLV +17%
matured Sep 12, 24
Wedbush ↗
Sep 13, 23
▲ Outperform · 🎯$137
Price at call : $113.78 — upside +20%
Today : $135.13 — upside +1%
Expected +20% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
+7.4%
stock +7% · XLV +17%
matured Sep 12, 24
JP Morgan ↗
Sep 13, 23
▲ Overweight · 🎯$134
Price at call : $114.3 — upside +17%
Today : $135.13 — upside -1%
Expected +17% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
+6.1%
stock +6% · XLV +17%
matured Sep 12, 24
▲ Overweight · 🎯$136
Price at call : $114.3 — upside +19%
Today : $135.13 — upside +1%
Expected +19% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+6.1%
stock +6% · XLV +17%
matured Sep 12, 24
▲ Overweight · 🎯$136
Price at call : $107.69 — upside +26%
Today : $135.13 — upside +1%
Expected +26% · Actual +42% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+41.7%
stock +42% · XLV +16%
matured Aug 21, 24
Oppenheimer ↗
Aug 21, 23
▲ Outperform · 🎯$154
Price at call : $108.32 — upside +42%
Today : $135.13 — upside +14%
Expected +42% · Actual +38% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+38.1%
stock +38% · XLV +16%
matured Aug 20, 24
▲ Buy · 🎯$132
Price at call : $103.29 — upside +28%
Today : $135.13 — upside -2%
Expected +28% · Actual +48% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+48.3%
stock +48% · XLV +14%
matured Aug 1, 24
Oppenheimer ↗
Aug 2, 23
▲ Outperform · 🎯$150
Price at call : $104.14 — upside +44%
Today : $135.13 — upside +11%
Expected +44% · Actual +47% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+47.1%
stock +47% · XLV +13%
matured Aug 1, 24
UBS ↗
Jul 13, 23
▲ Buy · 🎯$115
Price at call : $95.11 — upside +21%
Today : $135.13 — upside -15%
Expected +21% · Actual +55% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
+55.0%
stock +55% · XLV +12%
matured Jul 12, 24
▲ Buy · 🎯$130
Price at call : $97.4 — upside +33%
Today : $135.13 — upside -4%
Expected +33% · Actual +45% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+45.5%
stock +45% · XLV +6%
matured May 3, 24
Guggenheim ↗
May 4, 23
▲ Buy · 🎯$145
Price at call : $95.84 — upside +51%
Today : $135.13 — upside +7%
Expected +51% · Actual +47% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (6 calls matureds) · 📊 on Health : 69.8% · +22.2% (53 calls)
+46.8%
stock +47% · XLV +6%
matured May 3, 24
Oppenheimer ↗
May 2, 23
▲ Outperform · 🎯$150
Price at call : $103.45 — upside +45%
Today : $135.13 — upside +11%
Expected +45% · Actual +38% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+38.3%
stock +38% · XLV +5%
matured May 1, 24
Wedbush ↗
Apr 17, 23
▲ Outperform · 🎯$128
Price at call : $104.12 — upside +23%
Today : $135.13 — upside -5%
Expected +23% · Actual +28% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
+27.7%
stock +28% · XLV +3%
matured Apr 16, 24
UBS ↗
Apr 4, 23
▲ Buy · 🎯$125
Price at call : $100.38 — upside +25%
Today : $135.13 — upside -7%
Expected +25% · Actual +37% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
+37.1%
stock +37% · XLV +10%
matured Apr 3, 24
▲ Buy · 🎯$132
Price at call : $99.21 — upside +33%
Today : $135.13 — upside -2%
Expected +33% · Actual +43% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
+42.5%
stock +43% · XLV +14%
matured Mar 29, 24
Wedbush ↗
Feb 7, 23
▲ Outperform · 🎯$131
Price at call : $103.82 — upside +26%
Today : $135.13 — upside -3%
Expected +26% · Actual +31% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
+31.3%
stock +31% · XLV +9%
matured Feb 7, 24
▲ Overweight · 🎯$127
Price at call : $103.82 — upside +22%
Today : $135.13 — upside -6%
Expected +22% · Actual +31% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
+31.3%
stock +31% · XLV +9%
matured Feb 7, 24
JP Morgan ↗
Nov 3, 22
▲ Overweight · 🎯$143
Price at call : $121.82 — upside +17%
Today : $135.13 — upside +6%
Expected +17% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-6.4%
stock -6% · XLV -2%
matured Nov 3, 23
▲ Overweight · 🎯$132
Price at call : $122.06 — upside +8%
Today : $135.13 — upside -2%
Expected +8% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
-7.1%
stock -7% · XLV -3%
matured Nov 2, 23
UBS ↗
Oct 11, 22
▲ Buy · 🎯$136
Price at call : $107.6 — upside +26%
Today : $135.13 — upside +1%
Expected +26% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
+5.6%
stock +6% · XLV +7%
matured Oct 11, 23
JP Morgan ↗
Apr 4, 22
▲ Overweight · 🎯$126
Price at call : $97.05 — upside +30%
Today : $135.13 — upside -7%
Expected +30% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
+5.3%
stock +5% · XLV -3%
matured Apr 4, 23
Oppenheimer ↗
Dec 8, 21
▲ Outperform · 🎯$154
Price at call : $81.62 — upside +89%
Today : $135.13 — upside +14%
Expected +89% · Actual +44% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+43.6%
stock +44% · XLV +3%
matured Dec 8, 22
JP Morgan ↗
Nov 17, 21
▲ Overweight · 🎯$124
Price at call : $89.6 — upside +38%
Today : $135.13 — upside -8%
Expected +38% · Actual +28% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
+28.4%
stock +28% · XLV -1%
matured Nov 17, 22
Wedbush ↗
Apr 12, 21
▲ Outperform · 🎯$112
Price at call : $92.79 — upside +21%
Today : $135.13 — upside -17%
Expected +21% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
+5.6%
stock +6% · XLV +17%
matured Apr 12, 22
▲ Buy · 🎯$122
Price at call : $91.98 — upside +33%
Today : $135.13 — upside -10%
Expected +33% · Actual -5% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-4.6%
stock -5% · XLV +19%
matured Nov 12, 21
▲ Buy · 🎯$145
Price at call : $118.93 — upside +22%
Today : $135.13 — upside +7%
Expected +22% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-22.1%
stock -22% · XLV +25%
matured Aug 4, 21
▲ Overweight · 🎯$161
Price at call : $120.16 — upside +34%
Today : $135.13 — upside +19%
Expected +34% · Actual -22% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
-22.4%
stock -22% · XLV +26%
matured Aug 4, 21
JP Morgan ↗
Jun 18, 20
▲ Overweight · 🎯$134
Price at call : $128.83 — upside +4%
Today : $135.13 — upside -1%
Expected +4% · Actual -21% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-21.0%
stock -21% · XLV +24%
matured Jun 18, 21
▲ Buy · 🎯$134
Price at call : $113.16 — upside +18%
Today : $135.13 — upside -1%
Expected +18% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 67% (12 calls matureds) · 📊 on Health : 52.7% · +5.8% (93 calls)
-12.9%
stock -13% · XLV +28%
matured Jun 10, 21
Wedbush ↗
Jun 9, 20
▲ Outperform · 🎯$147
Price at call : $118.82 — upside +24%
Today : $135.13 — upside +9%
Expected +24% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 70% (10 calls matureds) · 📊 on Health : 39.4% · -0.3% (33 calls)
-17.2%
stock -17% · XLV +20%
matured Jun 9, 21
Oppenheimer ↗
Apr 13, 20
▲ Outperform · 🎯$130
Price at call : $95.95 — upside +35%
Today : $135.13 — upside -4%
Expected +35% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
-3.1%
stock -3% · XLV +26%
matured Apr 13, 21
Oppenheimer ↗
Jan 13, 20
▲ Outperform · 🎯$132
Price at call : $103.07 — upside +28%
Today : $135.13 — upside -2%
Expected +28% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+9.0%
stock +9% · XLV +14%
matured Jan 12, 21
JP Morgan ↗
Apr 22, 19
▲ Overweight · 🎯$106
Price at call : $80.08 — upside +32%
Today : $135.13 — upside -22%
Expected +32% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
+21.1%
stock +21% · XLV +13%
matured Apr 21, 20
▲ Overweight · 🎯$150
Price at call : $117.49 — upside +28%
Today : $135.13 — upside +11%
Expected +28% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 50% (10 calls matureds) · 📊 on Health : 56.4% · +17.2% (117 calls)
-16.9%
stock -17% · XLV -3%
matured Aug 23, 19
JP Morgan ↗
May 1, 18
▲ Overweight · 🎯$103
Price at call : $84.39 — upside +22%
Today : $135.13 — upside -24%
Expected +22% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on NBIX : 42% (12 calls matureds) · 📊 on Health : 49% · +7.1% (147 calls)
-11.7%
stock -12% · XLV +8%
matured May 1, 19
Oppenheimer ↗
Nov 2, 17
▲ Outperform · 🎯$85
Price at call : $73.48 — upside +16%
Today : $135.13 — upside -37%
Expected +16% · Actual +50% · Reason (≥ +15%) : ✓ Yes
🎯 on NBIX : 50% (12 calls matureds) · 📊 on Health : 54.3% · +4.5% (70 calls)
+50.4%
stock +50% · XLV +10%
matured Nov 2, 18

Frequently asked questions

Should I buy Neurocrine Biosciences stock?

This isn't buy advice. For Neurocrine Biosciences, the analyst consensus is "Buy", with an average price target of $210 (+55% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Neurocrine Biosciences). We show the numbers — you decide.

Is it too late to buy Neurocrine Biosciences? How high can it go?

The most bullish analyst target on Neurocrine Biosciences is $253 (+87% above today's price); the average is $210. That's the upside they see. Check how reliable those analysts have actually been on Neurocrine Biosciences on our site before trusting it.

Is Neurocrine Biosciences still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 24 analysts have a real record on Neurocrine Biosciences, the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Neurocrine Biosciences? The case for and against

The arguments for and against, one by one, from the numbers: why invest in NBIX (and why hesitate).

What has Neurocrine Biosciences's past performance been?

Historical returns and a "how much if I had invested" calculator: NBIX performance & returns.

What is the best month to buy NBIX?

The 12 months ranked by the stock's past returns: best & worst month to buy NBIX.

Are insiders buying NBIX stock?

Executives' and large holders' buys and sells, decoded: insider buying on NBIX.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)